Harlan Laboratories Continues Global Growth
News May 09, 2013
This expansion more than doubles the number of isolators at these sites allowing Harlan to meet growing customer demand for its immunocompromised models.
"Our investment in these facilities underscores our commitment to providing the highest quality research models and services to investigators across the globe," said Joe Meyer , Vice President Global Commercial Operations at Harlan Laboratories. "We will continue to expand and enhance our facilities worldwide to meet the needs of the research community in key therapeutic research areas like oncology, immunology and toxicology with consistently dependable research models, diets and supporting services."
These facilities incorporate the latest technology and design advances to ensure sustained high health status research models. The environmentally controlled breeding isolators are supported by individual air supply and HEPA filtered air handling to ensure the integrity of the colony housed within each isolator. The facilities also feature the latest state-of-the-art equipment and biosecurity measures including a watering system with automatic flushing to help prevent the unwanted proliferation of organisms, as well as a whole building redundant backup power system.
The expansion extends beyond an increase in facility footprint. Harlan Laboratories incorporated several sustainable components to the newly renovated Indianapolis and Livermore facilities.
"We designed the facilities with a dual purpose - animal care and sustainability. We have incorporated energy efficient lighting and water systems, as well as designed workflows to support our biosecurity practices," said Mike Lipke , Global Vice President of Operations at Harlan Laboratories. "We are very proud of these two additions to the Harlan network and look forward to our ability to meet increasing customer demand from these state-of-the-art facilities."
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018